ABSTRACT
Objective To explore the distribution characteristics of TCM syndrome and clinical relevant factors of benign prostatic hyperplasia (BPH).Methods Totally 781 cases of BPH patients were collected. Chi-square test, analysis of rank and inspection were used to detect the distribution characteristics of TCM syndrome. The multiple classification logistic regression was used to analyze related factors.Results BPH 14 kinds of distribution of syndromes were statistically significant (P<0.01). One of the highest incidence is qi deficiency and blood stasis syndrome (24.97%), and lung heat obstruction is the lowest (1.15%). Composite syndromes (529 cases) were more common than single syndrome (252 cases); syndromes of intermingled deficiency and excess (453 cases) were more common than simple excess (169 cases) or deficiency syndromes (159 cases). BPH single syndrome distribution was different in prostate volume, residual urine volume, maximum urine flow rate, and showed no difference in the serum PSA level. 3 logit model was established successfully. It was found that the patients with the features of 50 to 60 years old, the course < 3 years, I-PSS score for 8 to 19 points showed higher positive incidence of excess syndrome than intermingled deficiency and excess syndromes and deficiency syndrome.Conclusion This study reveals the BPH distribution characteristics and clinical related factors, which has guiding significance to improve TCM clinical level.
ABSTRACT
Objective To observe the mechanism of Zijin capsule on treating prostatitis. Methods Bacillary prostatitis rat model was made by injecting E.coil into prostate. The changes of serum TNF-?, IL-2, IL-8, IL-10 and mRNA expression of IL-8 and TNF-? in rat prostate were observed. Results Zijin capsule could reduce the serum TNF-?, IL-8 and prostate TNF-?, IL-8 mRNA expression in rat, increase the level of IL-2 and IL-10. Conclusion Zijin capsule could regulate the immune function of bacillary prostatitis rat model. Participation of immune regulation may be one of the treating mechanisms.